Skip to main content
Top
Published in: Rheumatology International 1/2016

01-01-2016 | Original Article - Epidemiology of RMD

Factors associated with atypical femoral fracture

Authors: Dam Kim, Yoon-Kyoung Sung, Soo-Kyung Cho, Minkyung Han, Yee-Suk Kim

Published in: Rheumatology International | Issue 1/2016

Login to get access

Abstract

We aimed to investigate the proportion of atypical femoral fractures (AFF) among Korean femoral fracture patients and examined the factors associated with the development of AFF. Between 2003 and 2013, 607 female patients with low-energy femoral fractures who were hospitalized at a single university hospital were retrospectively enrolled in this study. Patients were classified into two groups according to the fracture site: Patients with subtrochanteric or diaphyseal femoral fractures were included in the AFF group, while patients with intertrochanteric or neck fractures were included in the typical femoral fracture (TFF) group. After comparing clinical and radiographic characteristics between groups, we used multivariable logistic regression analysis to explore risk factors for AFF. Thirty patients (4.9 %) with AFF and 577 patients (95.1 %) with TFF were identified. The AFF group was younger than the TFF group (p < 0.01), and more patients with AFF were treated with bisphosphonate (BP) (p < 0.01) or proton-pump inhibitor (p = 0.02). When comparing the radiographic parameters, the AFF group tended to have a higher cortical thickness index (p = 0.02) and lateral-to-medial cortex ratio (p < 0.01). After adjusting for clinical variables, BP use (OR 8.09, CI 3.09–21.19) and younger age (OR 1.06, CI 1.01–1.11) were associated with AFF. The proportion of AFF was 4.9 % among patients with femoral fractures. Younger age and use of BP before fracture increased the risk of development of AFF in Korean patients.
Literature
1.
go back to reference Goh SK, Yang KY, Koh JS et al (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89:349–353PubMedCrossRef Goh SK, Yang KY, Koh JS et al (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89:349–353PubMedCrossRef
2.
go back to reference Giusti A, Hamdy NA, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 47:169–180PubMedCrossRef Giusti A, Hamdy NA, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 47:169–180PubMedCrossRef
3.
go back to reference Lee YK, Ha YC, Park C, Yoo JJ, Shin CS, Koo KH (2013) Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int 24:707–711PubMedCrossRef Lee YK, Ha YC, Park C, Yoo JJ, Shin CS, Koo KH (2013) Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int 24:707–711PubMedCrossRef
4.
go back to reference Wang Z, Bhattacharyya T (2011) Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007. J Bone Miner Res 26:553–560PubMedPubMedCentralCrossRef Wang Z, Bhattacharyya T (2011) Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007. J Bone Miner Res 26:553–560PubMedPubMedCentralCrossRef
5.
go back to reference Erviti J, Alonso A, Oliva B et al (2013) Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case-control study. BMJ Open 3:e002091PubMedPubMedCentral Erviti J, Alonso A, Oliva B et al (2013) Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case-control study. BMJ Open 3:e002091PubMedPubMedCentral
6.
go back to reference Gedmintas L, Solomon DH, Kim SC (2013) Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 28:1729–1737PubMedPubMedCentralCrossRef Gedmintas L, Solomon DH, Kim SC (2013) Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 28:1729–1737PubMedPubMedCentralCrossRef
7.
8.
go back to reference Perreault S, Dragomir A, Desgagne A et al (2005) Trends and determinants of antiresorptive drug use for osteoporosis among elderly women. Pharmacoepidemiol Drug Saf 14:685–695PubMedCrossRef Perreault S, Dragomir A, Desgagne A et al (2005) Trends and determinants of antiresorptive drug use for osteoporosis among elderly women. Pharmacoepidemiol Drug Saf 14:685–695PubMedCrossRef
9.
go back to reference Bilezikian JP (2009) Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 122:S14–S21PubMedCrossRef Bilezikian JP (2009) Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 122:S14–S21PubMedCrossRef
10.
go back to reference Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199PubMedCrossRef Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199PubMedCrossRef
11.
go back to reference Sim Ie W, Ebeling PR (2013) Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence. Ther Adv Musculoskelet Dis 5:259–267PubMedCrossRef Sim Ie W, Ebeling PR (2013) Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence. Ther Adv Musculoskelet Dis 5:259–267PubMedCrossRef
13.
go back to reference Cremers SC, Pillai G, Papapoulos SE (2005) Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44:551–570PubMedCrossRef Cremers SC, Pillai G, Papapoulos SE (2005) Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44:551–570PubMedCrossRef
14.
go back to reference Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759PubMedCrossRef Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759PubMedCrossRef
15.
go back to reference Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938PubMedCrossRef Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938PubMedCrossRef
16.
go back to reference Watts NB, Chines A, Olszynski WP et al (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365–372PubMedCrossRef Watts NB, Chines A, Olszynski WP et al (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365–372PubMedCrossRef
17.
go back to reference Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555–1565PubMedCrossRef Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555–1565PubMedCrossRef
19.
go back to reference Marcano A, Taormina D, Egol KA, Peck V, Tejwani NC (2014) Are race and sex associated with the occurrence of atypical femoral fractures? Clin Orthop Relat Res 472:1020–1027PubMedPubMedCentralCrossRef Marcano A, Taormina D, Egol KA, Peck V, Tejwani NC (2014) Are race and sex associated with the occurrence of atypical femoral fractures? Clin Orthop Relat Res 472:1020–1027PubMedPubMedCentralCrossRef
20.
go back to reference Lo JC, Huang SY, Lee GA et al (2012) Clinical correlates of atypical femoral fracture. Bone 51:181–184PubMedCrossRef Lo JC, Huang SY, Lee GA et al (2012) Clinical correlates of atypical femoral fracture. Bone 51:181–184PubMedCrossRef
21.
go back to reference Singh M, Nagrath AR, Maini PS (1970) Changes in trabecular pattern of the upper end of the femur as an index of osteoporosis. J Bone Joint Surg Am 52:457–467PubMed Singh M, Nagrath AR, Maini PS (1970) Changes in trabecular pattern of the upper end of the femur as an index of osteoporosis. J Bone Joint Surg Am 52:457–467PubMed
22.
go back to reference Dorr LD, Faugere MC, Mackel AM, Gruen TA, Bognar B, Malluche HH (1993) Structural and cellular assessment of bone quality of proximal femur. Bone 14:231–242PubMedCrossRef Dorr LD, Faugere MC, Mackel AM, Gruen TA, Bognar B, Malluche HH (1993) Structural and cellular assessment of bone quality of proximal femur. Bone 14:231–242PubMedCrossRef
23.
go back to reference Shane E, Burr D, Abrahamsen B et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23PubMedCrossRef Shane E, Burr D, Abrahamsen B et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23PubMedCrossRef
24.
go back to reference Saita Y, Ishijima M, Mogami A et al. (2015) The incidence of and risk factors for developing atypical femoral fractures in Japan. J Bone Miner Metab 33(3):311–318PubMedCrossRef Saita Y, Ishijima M, Mogami A et al. (2015) The incidence of and risk factors for developing atypical femoral fractures in Japan. J Bone Miner Metab 33(3):311–318PubMedCrossRef
25.
go back to reference Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294PubMedCrossRef Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294PubMedCrossRef
26.
go back to reference Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737PubMedCrossRef Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737PubMedCrossRef
27.
go back to reference Franceschetti P, Bondanelli M, Caruso G et al (2013) Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy. Bone 56:426–431PubMedCrossRef Franceschetti P, Bondanelli M, Caruso G et al (2013) Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy. Bone 56:426–431PubMedCrossRef
28.
go back to reference Annuurad E, Shiwaku K, Nogi A et al (2003) The new BMI criteria for asians by the regional office for the western pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J Occup Health 45:335–343CrossRef Annuurad E, Shiwaku K, Nogi A et al (2003) The new BMI criteria for asians by the regional office for the western pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J Occup Health 45:335–343CrossRef
29.
go back to reference Lenart BA, Neviaser AS, Lyman S et al (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353–1362PubMedPubMedCentralCrossRef Lenart BA, Neviaser AS, Lyman S et al (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353–1362PubMedPubMedCentralCrossRef
30.
go back to reference Chen F, Wang Z, Bhattacharyya T (2014) Absence of femoral cortical thickening in long-term bisphosphonate users: implications for atypical femur fractures. Bone 62:64–66PubMedPubMedCentralCrossRef Chen F, Wang Z, Bhattacharyya T (2014) Absence of femoral cortical thickening in long-term bisphosphonate users: implications for atypical femur fractures. Bone 62:64–66PubMedPubMedCentralCrossRef
31.
go back to reference Koeppen VA, Schilcher J, Aspenberg P (2012) Atypical fractures do not have a thicker cortex. Osteoporos Int 23:2893–2896PubMedCrossRef Koeppen VA, Schilcher J, Aspenberg P (2012) Atypical fractures do not have a thicker cortex. Osteoporos Int 23:2893–2896PubMedCrossRef
Metadata
Title
Factors associated with atypical femoral fracture
Authors
Dam Kim
Yoon-Kyoung Sung
Soo-Kyung Cho
Minkyung Han
Yee-Suk Kim
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 1/2016
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-015-3323-0

Other articles of this Issue 1/2016

Rheumatology International 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.